Get the live share price of Sarepta Therapeutics Inc (SRPT), including intraday charts, historical performance, key ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the ...

Sarepta Therapeutics (SRPT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Sarepta Therapeutics (SRPT Quick Quote SRPT - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the October 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Sarepta Therapeutics stock jumped 35% after early data from SRP-1001 and SRP-1003 trials. SRP-1001 and SRP-1003 showed strong target knockdown, dose-dependent delivery and safety. Sarepta Therapeutics ...

Sarepta Therapeutics recently filed a US$341.99 million shelf registration for 7,786,841 common shares tied to employee stock ownership, alongside shareholder approval of new 2026 equity incentive and ...

Sarepta Therapeutics (SRPT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...

Sarepta's Phase 3 ESSENCE study, which tested Amondys 45 and Vyondys 53 as treatments for Duchenne muscular dystrophy, failed to meet its primary endpoint of showing clear benefit over placebo. The ...

What To Know: Sarepta reported third-quarter revenue of $399.36 million, beating analyst estimates of $338.71 million, according to Benzinga Pro. The company reported a third-quarter adjusted loss of ...